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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 73, Revision 2 
(FGE.73Rev2): Consideration of alicyclic primary alcohols, aldehydes, 
acids and related esters evaluated by JECFA (59
th
 meeting) structurally 
related to primary saturated or unsaturated alicyclic alcohols, aldehydes, 
acids and esters evaluated by EFSA in FGE.12Rev3 (2012)
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
This scientific opinion, published on 5 December 2013, replaces the earlier version published on 16 October 
2013*. 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 17 alicyclic primary alcohols, aldehydes, acids and related esters and one phenethyl ester evaluated by 
the JECFA at the 59
th 
meeting in 2002. This revision is made due to consideration of two additional substances, 
santalyl acetate [FL-no: 09.034] and santalyl phenylacetate [FL-no: 09.712], cleared for genotoxicity concern in 
FGE.207. The substances were evaluated through a stepwise approach that integrates information on structure-
activity relationships, intake from current uses, toxicological threshold of concern, and available data on 
metabolism and toxicity. The Panel agrees with the application of the Procedure as performed by the JECFA for 
all 18 substances [FL-no: 02.114, 02.141, 05.098, 05.104, 05.112, 05.119, 05.123, 08.034, 08.060, 08.067, 
09.028, 09.034, 09.289, 09.488, 09.534, 09.536, 09.615 and 09.712], considered in this FGE and agrees with the 
JECFA conclusion, “No safety concern at estimated levels of intake as flavouring substances” based on the 
                                                     
1  On request from the European Commission, Question Nos EFSA-Q-2013-00552 and EFSA-Q-2013-00553, adopted on 25 
September 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares 
Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu   
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine 
Husøy, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing 
experts: Vibe Beltoft, Pia Lund and Karin Nørby and EFSA staff: Annamaria Rossi and Kim Rygaard Nielsen for the 
support provided to this scientific opinion. 
* Minor changes of editorial nature were made. The changes do not affect the contents of this report. To avoid confusion, the 
original version of the opinion has been removed from the website, but is available on request, as is a version showing all 
the changes made. 
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MSDI approach. Besides the safety assessment of these flavouring substances, the specifications for the 
materials of commerce have also been considered and for all 18 substances, the information is adequate. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
In the previous version of Flavouring Group Evaluation 73 (FGE.73), EFSA considered 16 alicyclic 
primary alcohols, aldehydes, acids and related esters evaluated by the JECFA at their 59
th
 meeting.  
This revision is made due to consideration of two additional substances, santalyl acetate [FL-no: 
09.034] and santalyl phenylacetate [FL-no: 09.712], compared to the previous version of FGE.73 
(FGE.73Rev1). These substances have been evaluated in FGE.207 due to structural concern for 
genotoxicity, and have been cleared from this concern and thus may be evaluated through the 
Procedure.  
The present consideration therefore concerns 17 alicyclic primary alcohols, aldehydes, acids and 
related esters and one phenethyl alcohol evaluated by the JECFA (59
th
 meeting) and will be considered 
in relation to the European Food Safety Authority (EFSA) evaluation of 10 primary saturated or 
unsaturated alicyclic alcohols, aldehydes and esters evaluated in the Flavouring Group Evaluation 12, 
Revision 3 (FGE.12Rev3). 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 18 
substances considered in this FGE. 
For all 18 substances evaluated through the Procedure use levels are needed to calculate the modified 
Theoretical Added Maximum Daily Intake (mTAMDI) in order to identify those flavouring substances 
that need more refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 18 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for all 18 JECFA 
evaluated substances.  
Thus, for all 18 substances [FL-no: 02.114, 02.141, 05.098, 05.104, 05.112, 05.119, 05.123, 08.034, 
08.060, 08.067, 09.028, 09.034, 09.289, 09.488, 09.534, 09.536, 09.615 and 09.712] the Panel agrees 
with the JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” 
based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008
4
 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5
. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6
. 
EFSA concluded that a genotoxic potential of the 11 α,β-unsaturated aldehydes and alcohol and 
related esters in the present FGE.201 could not be ruled out. 
Information on one representative material 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] 
has now been submitted by the European Flavour Association. This information is intended to cover 
also the re-evaluation of the following four substances from FGR.19 subgroup 2.1 (FGE.207): 
 12-beta-Santalen-14-ol [FL-no: 02.216] 
 12-alpha-Santalen-14-ol [FL-no: 02.217] 
 Santalyl acetate [FL-no: 09.034] 
 Santalyl phenylacetate [FL-no: 09.712]  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following five substances: 12-beta-santalen-14-ol [FL-no: 02.216], 12-alpha-
santalen-14-ol [FL-no: 02.217], santalyl acetate [FL-no: 09.034], santalyl phenylacetate [FL-no: 
09.712] and 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], in accordance with 
Commission Regulation (EC) No 1565/2000. 
INTERPRETATION OF THE TERMS OF REFERENCE  
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], first allocated to FGE.201, has 
subsequently been transferred to FGE.207 for evaluation with respect to genotoxicity. Based on the 
new genotoxicity data submitted, the Panel concluded that [FL-no: 09.931] does not give rise to 
concern with respect to genotoxicity. This conclusion can also be applied to the substances santalyl 
acetate [FL-no: 09.034] and santalyl phenylacetate [FL-no: 09.712] for which 2,6-dimethyl-2,5,7-
octatriene-1-ol acetate [FL-no: 09.931] is representative. Therefore, the European Commission request 
EFSA to carry out a safety assessment for 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], 
in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 
1-161. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the Opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65
th
 meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Flavouring Group Evaluation 73, Revision 2 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
The JECFA has evaluated a group of 26 flavouring substances consisting of alicyclic primary 
alcohols, aldehydes, acids and related esters (JECFA, 2002a).  
In FGE.73, which covered a group of 15 of the 26 JECFA-evaluated substances, the Panel considered 
that for nine substances [FL-no: 02.114, 02.141, 05.098, 05.112, 08.067, 09.289, 09.488, 09.534 and 
09.615] additional data were needed (no European production volumes available, preventing them to 
be evaluated using the Procedure, and/or missing data on isomerism/composition). For the remaining 
six of the 15 JECFA evaluated substances [FL-no: 05.119, 05.123, 08.034, 08.060, 09.028 and 09.536] 
the Panel agreed with the JECFA conclusion “no safety concern at estimated levels of intake as 
flavouring substances” based on the MSDI approach. 
The first revision of FGE.73 (FGE.73Rev1), included the assessment of one additional candidate 
substance, 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104]. No toxicity or 
metabolism data were provided for the substance. Furthermore, EU production volumes were provided 
for three substances [FL-no: 02.141, 09.488 and 09.534] (EFFA, 2010a). Additional information on 
stereoisomeric composition for six substances [FL-no: 02.114, 02.141, 05.098, 08.067, 09.289 and 
09.615] and further information on the composition for one substance [FL-no: 05.112] were received 
(EFFA, 2010b) after publication of FGE.73, information which was included in Revision 1. 
FGE Opinion adopted Link No. of substances 
FGE.73 6 March 2008 http://www.efsa.europa.eu/en/efsajournal/pub/868.htm  15 
FGE.73Rev1 22 March 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2638.htm  16 
FGE.73Rev2 25 September 2001  18 
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The present revision of FGE.73, FGE.73Rev2, includes the assessment of two additional flavouring 
substances, santalyl acetate [FL-no: 09.034] and santalyl phenylacetate [FL-no: 09.712]. These two 
substances have been considered with respect to genotoxicity in FGE.207 (EFSA CEF Panel, 2013a) 
and the Panel concluded that the data available did rule out the concern for genotoxicity and thus 
concluded that the substances can be evaluated through the Procedure.  
Santalyl phenylacetate [FL-no: 09.712] was evaluated by the JECFA at its 59
th
 meeting together with 
other phenethyl substances. With the exception of santanyl phenylacetate [FL-no: 09.712], these 
phenethyl substances were not α,β-unsaturated substances and were considered by EFSA in FGE.53 
with the conclusion “No safety concern at estimated levels of intake as flavouring substances” based 
on the MSDI approach. As the phenethyl part of the molecules was considered not to raise concern, 
the Panel concluded that after santalyl phenylacetate [FL-no: 09.712] was cleared from genotoxic 
concern in FGE.207, it could be included in the present FGE.73Rev2 together with the other santalyl 
substance (santalyl acetate [FL-no: 09.034]) from FGE.207. 
2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has at the 59
th
 meeting evaluated a group of 26 flavouring substances consisting of 
alicyclic primary alcohols, aldehydes, acids and related esters (JECFA, 2002a; JECFA, 2003).  
2.1.2. EFSA Considerations 
One of the 26 JECFA evaluated substances is not in the Register [Mixture of 2-methyl-5-(2,3-
dimethyltricyclo[2.2.1.0(2,6)]hept-3-yl)pent-2-en-1-ol and 2-methyl-5-(2-methyl-3-methylenebicyclo 
[2.2.1]hept-2-yl)pent-2-en-1-ol] (JECFA-no: 984).  
Ten substances [FL-no: 02.060, 02.091, 05.104, 05.106, 05.117, 05.121, 09.034, 09.272, 09.278 and 
09.302] are α,β-unsaturated aldehydes or may be metabolised to α,β-unsaturated aldehydes and have 
been considered together with other α,β-unsaturated aldehydes and ketones. One of these α,β-
unsaturated substances, 2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104], has 
been considered with respect to genotoxicity in FGE.209 (EFSA CEF Panel, 2011) and was evaluated 
through the Procedure in FGE.73Rev1. One additional substance, santalyl acetate [FL-no: 09.034], has 
been considered with respect to genotoxicity in FGE.207 (EFSA CEF Panel, 2013), and the Panel 
concluded that the data available ruled out the concern for genotoxicity and thus concluded that the 
substance can be evaluated through the Procedure in this revision of FGE.73. The genotoxic properties 
of the remaining eight of these 10 α,β-unsaturated carbonyl substances were considered together with 
other α,β-unsaturated aldehydes and ketones in FGE.208 (EFSA, 2008) for which it was concluded 
that additional data were required for all eight substances. 
The Panel also concluded that santalyl phenylacetate [FL-no: 09.712], evaluated by the JECFA at its 
59
th
 meeting together with other phenethyl substances, cleared for genotoxicity concern in FGE.207, 
should be included in this FGE.  
The Panel concluded that all 18 substances in this FGE are structurally related to the group of primary 
saturated or unsaturated alicyclic alcohol, aldehyde and esters evaluated by EFSA in the Flavouring 
Group Evaluation 12, Revision 3 (FGE.12Rev3). 
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2.2. Isomers 
2.2.1. Status 
Ten substances in the group of the JECFA evaluated alicyclic primary alcohols, aldehydes, acids and 
related esters have one or more chiral centres [FL-no: 02.114, 02.141, 05.098, 05.119, 05.123, 08.067, 
09.034, 09.289, 09.615 and 09.712]. 
2.2.2. EFSA Considerations 
For the two stereoisomeric substances [FL-no: 05.119 and 05.123], the CAS register number (CASrn) 
is considered to specify the stereoisomeric composition (Table 1). 
2.3. Specifications 
2.3.1.1. Status 
The JECFA specifications are available for all 18 substances (JECFA, 2002b) (See Table 1). 
2.3.2. EFSA Considerations 
The available specifications are considered adequate for all 18 substances (See Section 2.2). 
3. Intake Estimation 
3.1. Status 
For all 18 substances evaluated through the JECFA Procedure, intake data are available for the EU, 
see Table 4. 
 
Flavouring Group Evaluation 73, Revision 2 
 
EFSA Journal 2013;11(10):3393 10 
SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
02.114 
970 
2-(2,2,3-
Trimethylcyclopent-3-
enyl)ethan-1-ol 
 
3741 
 
1901-38-8 
Liquid 
C10H18O 
154.25 
Slightly soluble 
Miscible 
74 (0.8 hPa) 
 
NMR 
96 % 
1.470-1.478 
0.882-0.894 (20°) 
Racemate (EFFA, 
2010a). Synonym (+/-)-
campholene alcohol 
(EFFA, 2010a).  
02.141 
986 
2-(6,6-
Dimethylbicyclo[3.1.1]hep
t-2-en-2-yl)ethan-1-ol 
 
3938 
 
128-50-7 
Liquid 
C11H18O 
166.26 
Insoluble 
Miscible 
230 
 
IR NMR 
95 % 
1.490-1.500 
0.965-0.973 
Racemate (EFFA, 
2010a). 
05.098 
971 
p-Menth-1-en-9-al 
 
3178 
10347 
29548-14-9 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
95 (13 hPa) 
 
NMR 
99 % 
1.458-1.466 
0.904-0.916 (20°) 
Racemate (EFFA, 
2010a). 
05.104 
977 
2,6,6-Trimethylcyclohexa-
1,3-diene-1-carbaldehyde 
 
3389 
10383 
116-26-7 
Liquid 
C10H14O 
150.22 
Insoluble 
Miscible 
70 (1 hPa) 
 
NMR 
96 % 
1.525-1.533 
0.968-0.980 (20°) 
 
 
05.112 
978 
2,6,6-Trimethylcyclohex-
1-en-1-acetaldehyde 
 
3474 
10338 
472-66-2 
Liquid 
C11H18O 
166.26 
Insoluble 
Miscible 
58 (0.5 hPa) 
 
IR NMR 
92 % 
1.480-1.487 
0.873-0.885 (20°) 
Min. assay (92 %) 
secondary components 
ß-cyclocitral (2-3 %), ß-
ionone (0.5-1 %), methyl 
ß-homocyclogeranate (2-
4 %), ethyl ß-
homocyclogeranate (0.6-
1 %) (EFFA, 2010a). 
05.119 
967 
2,2,3-Trimethylcyclopent-
3-en-1-yl acetaldehyde 
 
3592 
10325 
4501-58-0 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
75 (137 hPa) 
 
NMR 
99 % 
1.462-1.469 
0.918-0.924 
CASrn in Register refers 
to (R)-isomer. 
Register name to be 
changed to (1R) 2,2,3-
Trimethylcyclopent-3-
en-1-yl acetaldehyde. 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
05.123 
968 
5-Isopropenyl-2-
methylcyclopentanecarbox
aldehyde 
 
3645 
 
55253-28-6 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
80 (14 hPa) 
 
IR 
95 % 
1.501-1.508 
0.940-0.952 (20°) 
CASrn in Register refers 
to (1R,2R,5S)-isomer. 
Register name to be 
changed to (1R,2R,5S) 5-
Isopropenyl-2-
methylcyclopentanecarb
oxaldehyde. 
08.034 
965 
Cyclohexylacetic acid 
 
2347 
34 
5292-21-7 
Solid 
C8H14O2 
142.20 
Slightly soluble 
Miscible 
242 
28-33 
NMR 
98 % 
1.459-1.467 
1.001-1.009 
 
 
08.060 
961 
Cyclohexanecarboxylic 
acid 
 
3531 
11911 
98-89-5 
Solid 
C7H12O2 
128.17 
Slightly soluble 
Miscible 
232-233 
28-32 
IR NMR 
98 % 
1.516-1.520 
1.029-1.037 
 
 
08.067 
976 
1,2,5,6-Tetrahydrocuminic 
acid 
 
3731 
 
71298-42-5 
Solid 
C10H16O2 
168.24 
Slightly soluble 
Soluble 
n.a. 
61 
NMR 
95 % 
n.a. 
n.a. 
Racemate (EFFA, 
2010a). CASrn in 
Register does not specify 
stereoisomeric 
composition. 
09.028 
964 
2-Cyclohexylethyl acetate 
 
2348 
218 
21722-83-8 
Liquid 
C10H18O2 
170.25 
Insoluble 
Miscible 
211 (996 hPa) 
 
NMR 
98 % 
1.442-1.450 
0.945-0.948 
 
 
09.034 
985 
Santalyl acetate 
 
3007 
224 
1323-00-8 
Liquid 
C17H26O2 
262.40 
Insoluble 
Miscible 
20.8 (4 hPa) 
 
IR 
95 % 
1.485-1.493 
0.980-0.986 
CASrn in Register refers 
to incompletely defined 
substance.  
60-65 % α-, 30-35 % β- 
form. 80-85 % Z versus 
15-20 % E (for the 
alpha) and 75-80 % Z 
versus 20-25 % E (for 
the beta) (EFFA, 2013). 
09.289 
969 
alpha-Campholene acetate 
 
3657 
 
36789-59-0 
Liquid 
C12H20O2 
196.29 
Insoluble 
Miscible 
96 (7 hPa) 
 
IR NMR 
98 % 
1.453-1.460 
0.943-0.949 
Commercial product (S)-
enantiomer (EFFA, 
2010a). Register name to 
be changed to (-)-
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
campholenyl acetate or 
(S)-campholenyl acetate 
(EFFA, 2010a). 
09.488 
966 
Ethyl 
cyclohexanepropionate 
 
2431 
2095 
10094-36-7 
Liquid 
C11H20O2 
184.28 
Insoluble 
Miscible 
91 (10 hPa) 
 
NMR 
98 % 
1.444-1.452 
0.926-0.932 
 
 
09.534 
963 
Ethyl 
cyclohexanecarboxylate 
 
3544 
11916 
3289-28-9 
Liquid 
C9H16O2 
156.22 
Insoluble 
Miscible 
82 (16 hPa) 
 
IR NMR 
99 % 
1.447-1.454 
0.966-0.978 (20°) 
 
 
09.536 
962 
Methyl 
cyclohexanecarboxylate 
 
3568 
11920 
4630-82-4 
Liquid 
C8H14O2 
142.19 
Insoluble 
Miscible 
183 
 
IR NMR 
98 % 
1.439-1.447 
0.990-0.999 
 
 
09.615 
972 
p-Menth-1-en-9-yl acetate 
 
3566 
10748 
28839-13-6 
Liquid 
C12H20O2 
196.28 
Insoluble 
Miscible 
228-232 
 
NMR 
97 % 
1.441-1.448 
0.931-0.937 
Racemate (EFFA, 
2010a). 
09.712 
1022 
Santalyl phenylacetate 
 
3008 
239 
1323-75-7 
Liquid 
C23H30O2 
338.49 
Insoluble 
Miscible 
328 
 
NMR 
98 % 
1.525-1.576 
1.022-1.029 
CASrn in Register refers 
to incompletely defined 
substance.  
60-65 % α-, 30-35 % β- 
form. 80-85 % Z versus 
15-20 % E (for the 
alpha) and 75-80 % Z 
versus 20-25 % E (for 
the beta) (EFFA, 2013).  
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text Taken7 from the JECFA Report (JECFA, 2003) 
No data on genotoxicity were available for the JECFA-evaluated substances. As these substances are 
rapidly metabolised in vivo to compounds of lower toxicological potential, the Committee concluded 
that the monocyclic and bicyclic terpenes with alkyl ring substituents and containing an alcohol, 
aldehyde or carboxylic acid group would have little genotoxic potential in vivo. 
4.2. Genotoxicity Studies – Text Taken8 from EFSA FGE.12Rev3 (EFSA CEF Panel, 2012a) 
There are no studies available on genotoxicity neither for the 10 candidate substances nor for the 15 
supporting substances. The genotoxic potential of this group of flavouring substances can therefore not 
be assessed properly. However, this does not preclude evaluation of the candidate substances in the 
present group using the Procedure. 
4.3. Genotoxicity Studies – Text Taken9 from EFSA FGE.209 (EFSA CEF Panel, 2011) 
The Industry has submitted data concerning genotoxicity studies for 2,6,6-trimethylcyclohexa-1,3-
diene-1-carbaldehyde [FL-no: 05.104] (safranal), which is the only substance considered in FGE.209. 
In Vitro Data 
In vitro genotoxicity assays have been performed on the α,β-unsaturated aldehyde safranal [FL-no: 
05.104]. 
Bacterial Reverse Mutation Assay 
Safranal has been tested for its ability to induce gene mutations in the bacterial reverse mutation assay 
according to OECD Guideline 471 (Beevers, 2010) (for details, see Table 2). The concentrations used 
in the different experiments were based on concentrations observed to give toxic effects in previous 
experiments. Positive and negative controls were included in all experiments according to current 
guidelines. 
There were some increases in revertant numbers in TA102 in the absence and presence of S9 in the 
first experiment, but these were of insufficient magnitude to be considered as evidence of 
mutagenicity, they were not concentration-related, and were not reproducible in the other experiments. 
In all other strains there was no evidence of mutagenic activity either in the absence or presence of S9 
in any of the experiments. 
It is concluded that under the test conditions applied safranal did not induce gene mutations in 
bacteria. 
Micronucleus Assays 
Safranal was evaluated in an in vitro micronucleus assay in human peripheral blood lymphocytes for 
its ability to induce chromosomal damage or aneuploidy in the presence and absence of S9 (Whitwell, 
2010). The maximum soluble concentration of 1250 μg/ml was selected as the maximum 
concentration for the cytotoxicity range finder test. The concentrations in the main tests were based on 
toxicity shown in this range finding study (for details, see Table 2).  
                                                     
7 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
8 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
9 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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At the highest concentration used in the 3 + 21 hours treatment in the presence of S9, a small statistical 
increase in the frequency of micronucleated binucleate cells (MNBN) was observed, but this was set 
against a low mean concurrent vehicle control response. This concentration induced 62 % cytotoxicity, 
and there was no statistically significant increase in MNBN at the next lowest concentration, which 
induced 42 % cytotoxicity. Therefore, this isolated increase was not considered to be of biological 
importance. Outside of this isolated observation at a high level of toxicity, no evidence of 
chromosomal damage or aneuploidy was observed in terms of any increase in the frequency of MNBN 
in the presence or absence of S9.  
It is concluded that under the conditions of this study, safranal did not induce micronuclei in cultured 
human lymphocytes. 
In Vivo Data 
Based on the in vitro data available, no in vivo data are needed. 
Discussion of Mutagenicity/Genotoxicity Data 
2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104] was tested for all three genetic 
endpoints, gene mutations, structural and numerical chromosomal aberrations. The substance did not 
induce gene mutations in bacteria and was not clastogenic and/or aneugenic in mammalian cells in 
vitro.  
Although this flavouring substance showed evidence of cytotoxicity at high concentrations, it did not 
induce biologically significant genotoxic responses.  
For validation and study results, see Table 2. 
Conclusion on Genotoxicity and Carcinogenicity 
The in vitro genotoxicity data on 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104] 
do not indicate genotoxic potential. 2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 
05.104] will then be evaluated through the Procedure in FGE.73Rev1. 
4.4. Genotoxicity Studies – Text Taken10 from EFSA FGE.207 (EFSA CEF Panel, 2013a) 
The Industry has submitted data concerning genotoxicity studies (EFFA, 2012) for one substance 2,6-
dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] of FGE.19 subgroup 1.1.2 (FGE.201). These 
data will cover four substances [FL-no: 02.216, 02.217, 09.034 and 09.712] from FGE.19 subgroup 
2.1, evaluated in FGE.207.  
The new data submitted for 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] covers in vitro 
assays in bacteria and mammalian cell systems. 
In Vitro Data 
Bacterial Reverse Mutation Assay 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 to assess the mutagenicity of 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], 
both in the absence and in the presence of metabolic activation by S9-mix (from livers of rats induced 
with Aroclor 1254), in three experiments (King, 2000). An initial experiment was carried out in the 
absence and presence of S9-mix in the five strains, using final concentrations of 2,6-dimethyl-2,5,7-
                                                     
10 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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octatriene-1-ol acetate at 5 - 5000 μg/plate in the presence of S9-mix activation and 5 - 1500 μg/plate 
in the absence of S9-mix, plus negative (solvent) and positive controls. The standard plate 
incorporation assay was used. Evidence of toxicity, in terms of a decrease in revertant count, was 
apparent on all plates treated at 500 μg/plate and above in the absence of S9-mix. In the presence of 
S9-mix, the test article was toxic at concentrations of 1500 μg/plate and above for strains TA1537 and 
TA102, and at 5000 μg/plate for strains TA98, TA100 and TA1535. In all cases revertant counts were 
obtained from at least four different concentrations, and so these data were considered valid for 
mutation assessment. In the absence of S9-mix activation, no statistically significant increases in 
revertant numbers were observed in any of the test strains. In the presence of S9-mix activation no 
statistically significant increases in revertant numbers were observed for strains TA98, TA100, 
TA1535 or TA1537, but very small increases in revertant numbers were observed in strain TA102 at 
15 and 50 μg/plate which, although statistically significant (p ≤ 0.05), amounted to only 1.17-fold and 
1.18-fold increases over background, respectively. Furthermore, no increases were observed at the 
higher test concentrations of 150 and 500 μg/plate. 
In a second confirmatory experiment using the same conditions, no statistically significant increases in 
revertant numbers were observed at any concentration in any of the strains, either in the presence or 
absence of S9-mix activation. To further investigate the potential mutagenic effect in strain TA102 in 
the presence of S9-mix activation, a third experiment was conducted in that strain only. No 
statistically significant increases in revertant numbers were observed at any concentration tested. 
On this basis, the very small increases seen in only a single experiment at the two lower test 
concentrations in the presence of S9-mix activation in strain TA102 were not reproducible or 
concentration-related, and were therefore considered to be chance occurrences and not related to 
treatment with 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] (King, 2000). It was 
concluded that 2,6-dimethyl-2,5,7-octatriene-1-ol acetate did not induce mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium when tested under 
the conditions of this study. These conditions included treatments at concentrations up to either the 
limit of toxicity or 5000 μg/plate (the maximum recommended concentration, according to current 
regulatory guidelines), in the absence and in the presence of a rat liver metabolic activation system 
(S9-mix). 
Micronucleus Assays 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] was assayed for the induction of 
chromosome damage and potential aneugenicity in mammalian cells in vitro by examining the effect 
of compound treatment on the frequency of micronuclei in cultured human peripheral blood 
lymphocytes (whole blood cultures pooled from two healthy male volunteers in two separate 
experiments) treated in the absence and presence of a metabolising system (S9-mix) from livers of rats 
induced with Aroclor 1254 (Whitwell, 2012). 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate was added at 48 hours following culture initiation 
(stimulation by phytohaemagglutinin) either for 3 hours treatment in the absence or presence of S9-
mix plus 21 hours recovery, or for 24 hours treatment in the absence of S9-mix without recovery. 
Cytochalasin B (6 μg/ml) was added at the start of the 24-hour continuous treatment, or at the start of 
the 21-hour recovery periods following the 3-hour treatments, in order to block cytokinesis and 
generate binucleate cells for analysis. It remained in the cultures until they were harvested 24 hours 
after the start of treatment. A preliminary range-finding experiment had been conducted with and 
without S9-mix treatment in order to determine the effect of treatment upon Replication Index (RI), 
which was used as a basis for choosing a range of concentrations to be evaluated in Experiments 1 and 
2. 
In all of the different treatment conditions and separate experiments, frequencies of micronucleated 
binucleate cells (MNBN) were normal in negative controls and were significantly increased by 
treatment with the positive control chemical. 
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In Experiment 1, all three different treatment conditions described above were investigated. In the first 
treatment condition, 2,6-dimethyl-2,5,7-octatriene-1-ol acetate was added for 3 hours in the absence of 
S9-mix at concentrations of 70, 85, 100 or 120 μg/mL along with positive and negative controls, 
followed by 21 hours recovery. No significant increases in the frequency of MNBN were observed 
relative to concurrent vehicle controls at any of the concentrations analysed. Furthermore, the MNBN 
cell frequencies in all treated cultures under this treatment condition fell within the 95
th
 percentile of 
the normal range. 
In the second treatment condition, following 24 hours continuous treatment at 20, 40 or 60 μg/mL in 
the absence of S9-mix without recovery, no increases in the frequency of MNBN cells were obtained 
that were significantly higher (p ≤ 0.05) than those observed in concurrent controls. Furthermore, the 
MNBN cell frequencies in all treated cultures under this treatment condition fell within the 95
th
 
percentile of the normal range. 
In the third treatment condition, following 3 hours treatment with 2,6-dimethyl-2,5,7-octatriene-1-ol 
acetate at concentrations of 120, 140, 180 or 225 μg/mL in the presence of S9-mix, followed by 21 
hours recovery, the frequency of MNBN cells were significantly higher (p ≤ 0.05) than concurrent 
controls at the top concentration analysed. This concentration induced a 57 % mean level of 
cytotoxicity, which is close to the recommended upper limit for this test procedure. Furthermore, 
increases in the frequency of MNBN cells were only seen in one replicate (A) where only 394 
binucleate cells could be analysed for this test concentration, where cytotoxicity actually exceeded 60 
%, and where examination of the slides indicated a concentration-related effect on cells without intact 
cytoplasm. This may have resulted in an underestimation of the cytotoxicity, but it was not observed in 
the other replicate culture (B). 
In Experiment 2, the weak induction of micronuclei that was observed in Experiment 1 in the presence 
of S9-mix was further investigated. Following treatment for 3 hours followed by 21 hours recovery in 
the presence of S9-mix with 2,6-dimethyl-2,5,7-octatriene-1-ol acetate at concentrations of 119.2, 180, 
250 or 290 μg/mL, which induced 5 %, 19 %, 39 % and 54 % cytotoxicity, respectively, small but 
statistically significant (p ≤ 0.05) increases in MNBN cell frequencies were observed at the lowest and 
highest concentrations analysed. At the highest concentration analysed only a single replicate culture 
gave MNBN cell frequencies that exceeded normal historical control values, and it is also noteworthy 
that the vehicle control frequency was quite low for this particular experiment which might have 
contributed to the test outcome. Furthermore, additional analysis of spare slides from the replicate 
cultures at the lowest and highest concentrations analysed resulted in the overall micronucleus 
frequencies falling within normal ranges. On this basis, the weak statistical significance observed in 
the first experiment was not reproduced at higher concentrations and similar levels of toxicity, and was 
therefore not considered to be of biological relevance. 
In conclusion, 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] was not considered to 
demonstrate induction of micronuclei in a robust study that achieved required levels of toxicity 
(Whitwell, 2012). 
Conclusion 
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] did not induce any biologically significant 
increases in bacterial mutation when evaluated in an Ames test in the presence and absence of S9 
metabolic activation. It did induce weak genotoxic effects in the in vitro micronucleus assay in an 
initial experiment in the presence of S9-mix at the highest concentration only. In a second experiment, 
although statistically significant increases were observed at the lowest and highest concentrations 
tested, these increases fell within the historical control range for the testing laboratory, and were not 
considered to be biologically important. The Panel therefore concluded that 2,6-dimethyl-2,5,7-
octatriene-1-ol acetate [FL-no: 09.931], from subgroup 1.1.2 of  FGE.19 (FGE.201), does not give rise 
to concern with respect to genotoxicity and can accordingly be evaluated through the Procedure. 
Furthermore, as 2,6-dimethyl-2,5,7-octatriene-1-ol acetate is considered representative for the four 
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precursors for α,β-unsaturated alicyclic aldehydes [FL-no: 02.216, 02.217, 09.034 and 09.712] from 
subgroup 2.1 of FGE.19 (FGE.207), the genotoxicity concern can also be lifted for these four 
substances and accordingly they can also be evaluated through the Procedure as well (in FGE.12Rev4 
and FGE.73Rev2). 
For a summary of in vitro genotoxicity data considered by the EFSA in FGE.207, see Table 3. 
4.5. EFSA Considerations 
The present revision of FGE.73, Revision 2, contains 18 substances, which includes the assessment of 
two additional flavouring substances, santalyl acetate [FL-no: 09.034] and santalyl phenylacetate [FL-
no: 09.712]. These substances have a structural alert for genotoxicity, but this concern has been 
alleviated as described in FGE.207 (EFSA CEF Panel, 2013a), where the Panel based on submitted 
data on the representative substance 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] 
concluded that it does not give rise to concern with respect to genotoxicity. This conclusion can also 
be applied to the substances santalyl acetate [FL-no: 09.034] and santalyl phenylacetate [FL-no: 
09.712] for which 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] is representative. 
Therefore, these substances can also be evaluated through the Procedure in this FGE.73Rev2 ([FL-no: 
09.931] is evaluated through the Procedure in FGE.72Rev1(EFSA CEF Panel, 2013b)). No 
genotoxicity data are available for any of the remaining 16 JECFA evaluated substances. However, 
this will not preclude the evaluation of these substances using the Procedure, and the Panel agreed 
with the JECFA that these 16 substances can be evaluated using the Procedure. 
5. Application of the Procedure 
5.1. Application of the Procedure to 17 Alicyclic Primary Alcohols, Aldehydes, Acids and 
Related Esters and One Ester of a Phenethyl Derivative by the JECFA (JECFA, 2002a) 
According to the JECFA all 18 substances belong to structural class I using the decision tree approach 
presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded for 16 of the alicyclic primary alcohols, aldehydes, acids and related esters and 
for santalyl phenylacetate [FL-no: 09.712], an ester of the phenethyl derivatives, at step A3 in the 
JECFA Procedure – i.e. the substances are expected to be metabolised to innocuous products (step 2) 
and the intakes for all substances are below the thresholds for their structural class I (step A3). 
The JECFA concluded for 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104] 
(safranal) at step B4 in the JECFA Procedure – i.e. the substance cannot be expected to be metabolised 
to innocuous products (step 2) and an adequate NOAEL exists to provide a margin of safety (step B4). 
This evaluation was reached by the following procedure: Step B3. The daily per capita intake of the 
monocyclic substance with two endocyclic double-bonds evaluated at this step, 2,6,6-
trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104], was below the threshold for daily 
human intake of compounds of structural class I, and its evaluation therefore proceeded to step B4. 
Step B4. As the agent evaluated at this step, 2,6,6-trimethy1cyclohexa-l,3-diene-1-carbaldehyde [FL-
no: 05.104] (safranal), is structurally related to perillyl alcohol [FL-no: 02.060], data on the toxicity of 
perillyl alcohol were used to evaluate its safety. Perillyl alcohol given by intragastric gavage changed 
the weights of several organs in female rats when given at 400 mg/kg bw per day, but not at 120 
mg/kg bw per day, in a 90-day study; changes in organ weights were not reported in male rats. Doses 
of 40, 120 and 400 mg/kg bw per day produced hyperexcitability and salivation, which the authors 
considered may have been due to its irritating properties (National Cancer Institute, 1996). A daily 
dose of 120 mg/kg bw was well tolerated by dogs in a 90-day study (National Cancer Institute, 1996). 
The daily intake of 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104] (safranal) is 
0.058 µg/kg bw in Europe and 0.001 µg/kg bw in the USA. The margin of safety between these 
intakes and 120 mg/kg bw per day is > 2000000. The compound also shares structural similarities with 
alpha-ionone and beta-ionone [FL-no: 07.007] and [FL-no: 07.008], which were evaluated by the 
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Committee at its fifty-first meeting (JECFA, 2000). The NOELs for these compounds were 10 mg/kg 
bw per day in a 90-day study in rats, providing a margin of safety of about 200000. Therefore, 2,6,6-
trimethylcyclohexa-1,3-diene-1-carbaldehyde [FL-no: 05.104] (safranal) would not be a safety 
concern. 
In conclusion, the JECFA evaluated all 18 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 18 substances are summarised in Table 4: Summary of Safety Evaluation by the 
JECFA (JECFA, 2003). 
5.2. Application of the Procedure to Ten Primary Saturated or Unsaturated Alicyclic 
Alcohol, Aldehyde and Esters by EFSA in FGE.12Rev3 (EFSA CEF Panel, 2012a) 
Ten candidate substances were evaluated in FGE.12Rev3. All 10 substances were classified into 
structural class I, using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
It was anticipated that all 10 substances will be metabolised to innocuous products at the estimated 
levels of intake and accordingly proceed via the A-side of the Procedure. The estimated daily per 
capita intakes of the 10 substances range from 0.011 to 43 µg, which is below the threshold of concern 
of 1800 µg/person/day for structural class I. 
The Panel concluded all substances in FGE.12Rev3 at step A3 as to be of no safety concern at the 
estimated levels of intake as flavouring substances based on the MSDI approach. 
The stepwise evaluations of the 10 substances are summarised in Table 5: Summary of Safety 
Evaluation Applying the Procedure (EFSA CEF Panel, 2012a). 
5.3. EFSA Considerations 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 18 
substances in the group of alicyclic primary alcohols, aldehydes, acids and related esters.  
The Panel noted that one substance [FL-no: 05.123] has a terminal double bond. Although 
theoretically, the double bond may be oxidised to give reactive epoxides, it is expected that for this 
substance, the metabolism via this pathway is negligible, since the terminal double bond is present in a 
molecule that has an aldehyde function at the end distal from the double bond. The aldehyde function 
is expected to be readily attacked by oxidation processes, ultimately yielding unsaturated carboxylic 
acids. Biochemical attack of these carboxylic acids via e.g. beta-oxidation or conjugation with 
glucuronic acid is expected to be much more efficient and rapid than microsomal oxidation. 
CONCLUSION 
In Flavouring Group Evaluation 73, Revision 1 (FGE.73Rev1), the EFSA considered 16 flavouring 
substances (EFSA CEF Panel, 2012a) from a group of 26 alicyclic primary alcohols, aldehydes, acids 
and related esters evaluated by the JECFA of at the 59
th
 meeting in 2002 (JECFA, 2002a). The present 
revision of FGE.73, FGE.Rev2, includes the consideration of two additional substances, santalyl 
acetate [FL-no: 09.034] and santalyl phenylacetate [FL-no: 09.712]. These substances were considered 
with respect to genotoxicity in FGE.207 (EFSA CEF Panel, 2013a), and the Panel concluded that the 
data available ruled out the concern for genotoxicity and thus concluded that the substances can be 
evaluated through the Procedure. 
Therefore, the present revision of FGE.73Rev2 considers 18 flavouring substances evaluated by the 
JECFA. 
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The Panel concluded that the 18 substances are structurally related to the group of 10 primary 
saturated or unsaturated alicyclic alcohol, aldehyde and esters evaluated by EFSA in the Flavouring 
Group Evaluation 12, Revision 3 (FGE.12Rev3).  
The Panel agrees with the application of the Procedure as performed by the JECFA for the 18 
substances considered in this FGE. 
For all 18 substances evaluated through the Procedure use levels are needed to calculate the 
mTAMDIs in order to identify those flavouring substances that need more refined exposure 
assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 18 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for all 18 JECFA 
evaluated substances.  
Thus, for all 18 substances [FL-no: 02.114, 02.141, 05.098, 05.104, 05.112, 05.119, 05.123, 08.034, 
08.060, 08.067, 09.028, 09.034, 09.289, 09.488, 09.534, 09.536, 09.615 and 09.712] the Panel agrees 
with the JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” 
based on the MSDI approach. 
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (in vitro) EFSA / FGE.209 (EFSA CEF Panel, 2011) 
FL-no Chemical Name Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
[05.104] 2,6,6-
Trimethylcyclohexa-1,3-
diene-1-carbaldehyde 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
1.6, 8, 40, 200, 1000, 5000 
μg/plate   
Negative 4 (Beevers, 
2010) 
Valid study. First experiment: 
Standard plate ± S9. Toxicity was 
observed in all strains with and 
without S9 at 5000 μg/plate and in 
TA1537 and TA102 with S9 at 
1000 μg/plate. 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
125, 250, 500, 1000, 2000, 
5000 μg/plate 
Negative 4 (Beevers, 
2010) 
Valid study. Second experiment: 
Standard plate without S9. Toxicity 
was observed at 2000 μg/plate and 
above. 
S. typhimurium TA98, 
TA100 and TA1535 
62.5, 125, 250, 500, 1000, 
2000, 5000 μg/plate 
Negative 4 (Beevers, 
2010) 
Valid study. Second experiment 
with S9 and preincubation: 
Toxicity was observed at 500 
μg/plate and above. 
S. typhimurium TA1537 
and TA102 
62.5, 125, 250, 500, 1000, 
2000 μg/plate 
Negative 4 (Beevers, 
2010) 
Valid study. Second experiment 
with S9 and preincubation: 
Toxicity was observed at 500 
μg/plate and above. 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
15.625, 31.25, 62.5, 125, 
250, 500 μg/plate 
Negative 4 (Beevers, 
2010) 
Valid study. Third experiment with 
S9 and preincubation: Toxicity was 
observed at 250 μg/plate and 
above.  
Micronucleus 
induction 
Human peripheral blood 
lymphocytes 
0, 40, 60, 90 μg/ml1 Negative 5 (Whitwell, 
2010) 
Valid study. 
0, 80, 100, 120, 140 μg/ml2 
0, 4, 8, 12 μg/ml3 
1) 3 hours treatment 21 hours recovery without S9. 
2) 3 hours treatment 21 hours recovery with S9. 
3) 24 hours treatment no recovery without S9. 
4) The assays were performed according to OECD Guideline 471 and in compliance with GLP. 
5) This assay is performed in accordance with OECD 487.    
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Table 3:  Summary of Additionally Genotoxicity Data for [FL-no: 09.931] of Subgroup 1.1.2 
Chemical Name 
[FL-no:] 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
2,6-Dimethyl-2,5,7-
octatriene-1-ol acetate 
[09.931] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
 
5 - 1500 μg/plate 
[1,3]; 
5 - 5000 μg/plate 
[2,3] 
Negative 
[1,3]; 
Equivocal 
[2,3] 
(King, 2000) Reliable without restriction. GLP study in 
compliance with OECD Guideline 471. A 
small increase in TA102 revertant numbers 
was seen at 15 and 50 μg/plate in the 
presence of S9-mix, but not at higher 
concentrations. 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
 
5 - 1500 μg/plate 
[1,3]; 
5 - 5000 μg/plate 
[2,3] 
Negative 
[1,3]; 
Negative 
[2,3] 
The small increase in TA102 revertant 
numbers seen in the first experiment at 15 and 
50 μg/plate in the presence of S9-mix was not 
reproduced in the second experiment. 
S. typhimurium TA102 5 - 1500 μg/plate 
[2,3] 
 
Negative The small increase in TA102 revertant 
numbers seen in the first experiment at 15 and 
50 μg/plate in the presence of S9-mix was not 
reproduced in the third experiment. 
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes (Male 
Donors) 
70 - 120 μg/ml 
[1,4]; 
120-225 μg/mL [2,4]; 
20 - 60 μg/mL  
[1,5]; 
119.2 - 290 μg/mL 
[2,4] 
Weak positive 
+S9; 
Re-test within 
normal values 
(Whitwell, 2012) Reliable without restriction. GLP study in 
compliance with OECD Guideline 487. Weak 
evidence of inducing micronuclei in the 
presence of S9-mix in a first experiment 
(increases only in one culture). A re-test 
under the same conditions and using a higher 
top concentration resulted in MNBN 
frequencies within the historical negative 
control range at 95th percentile, but were 
statistically significant due to low vehicle 
control values.  
[1] Without S9-mix metabolic activation. 
[2] With S9-mix metabolic activation. 
[3] Plate incorporation method. 
[4] 3 hour incubation with 21-hour recovery period. 
[5] 24 hour incubation with no recovery period. 
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SUMMARY OF SAFETY EVALUATIONS 
Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2003) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation 
procedure path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
02.114 
970 
2-(2,2,3-
Trimethylcyclopent-3-
enyl)ethan-1-ol  
0.012 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
02.141 
986 
2-(6,6-
Dimethylbicyclo[3.1.1]h
ept-2-en-2-yl)ethan-1-ol 
 
33 
0.01 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
05.098 
971 
p-Menth-1-en-9-al 
 
0.12 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
05.104 
977 
2,6,6-
Trimethylcyclohexa-1,3-
diene-1-carbaldehyde 
 
3.5 
0.07 
Class I 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
4) Evaluated in FGE.209. 
Genotoxicity concern could 
be ruled out (EFSA, 2011). 
No safety concern at the 
estimated level of intake 
based on the MSDI approach.  
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
05.112 
978 
2,6,6-
Trimethylcyclohex-1-en-
1-acetaldehyde 
 
0.24 
2 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
According to JECFA: Min. assay 
value is "92 %".  Secondary 
components ß-cyclocitral (2-3 
%), ß-ionone (0.5-1 %), methyl ß-
homocyclogeranate (2-4 %), ethyl 
ß-homocyclogeranate (0.6-1 %) 
(EFFA, 2010a).  
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
05.119 
967 
2,2,3-
Trimethylcyclopent-3-
en-1-yl acetaldehyde 
 
5.0 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
CASrn in Register refers to (R)-
isomer. 
Register name to be changed to 
(1R) 2,2,3-Trimethylcyclopent-3-
en-1-yl acetaldehyde.  
No safety concern at the 
estimated level of intake based on 
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Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2003) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation 
procedure path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
the MSDI approach. 
05.123 
968 
5-Isopropenyl-2-
methylcyclopentanecarb
oxaldehyde 
 
0.012 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
CASrn in Register refers to 
(1R,2R,5S)-isomer. 
Register name to be changed to 
(1R,2R,5S) 5-Isopropenyl-2-
methylcyclopentanecarboxaldehy
de.  
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
08.034 
965 
Cyclohexylacetic acid 
 
0.12 
0.4 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
08.060 
961 
Cyclohexanecarboxylic 
acid 
 
0.061 
4 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
08.067 
976 
1,2,5,6-
Tetrahydrocuminic acid 
 
0.012 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.028 
964 
2-Cyclohexylethyl 
acetate 
 
0.97 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.034 
985 
Santalyl acetate 
 
0.1 
0.01 
Class I 
A3: Intake below 
threshold 
4) Evaluated in FGE.207. No 
safety concern at the 
estimated level of intake 
based on the MSDI approach. 
CASrn in Register refers to 
incompletely defined substance  
According to JECFA: Min. assay 
value is ”95 %” and secondary 
components ”60-65 % α-, 30-
35% β-form”.  
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.289 
969 
alpha-Campholene 
acetate 
 
0.061 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
Register name to be changed to 
(-)-campholenyl acetate or (S)-
campholenyl acetate.  
No safety concern at the 
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Table 4:  Summary of Safety Evaluation by the JECFA (JECFA, 2003) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
( g/capita/day) 
Class 2) 
Evaluation 
procedure path 3) 
Outcome on 
the named 
compound [4) 
or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
estimated level of intake based on 
the MSDI approach. 
09.488 
966 
Ethyl 
cyclohexanepropionate 
 
0.12 
0.1 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.534 
963 
Ethyl 
cyclohexanecarboxylate 
 
0.24 
0.1 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.536 
962 
Methyl 
cyclohexanecarboxylate 
 
0.073 
0.01 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.615 
972 
p-Menth-1-en-9-yl 
acetate 
 
0.85 
ND 
Class I 
A3: Intake below 
threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
09.712 
1022 
Santalyl phenylacetate 
 
0.029 
1 
Class I 
A3: Intake below 
threshold 
4) Evaluated in FGE.207. No 
safety concern at the 
estimated level of intake 
based on the MSDI approach. 
CASrn in Register refers to 
incompletely defined substance  
According to JECFA 60-65 % is 
on α-form and 30-35 % on β-
form. 
No safety concern at the 
estimated level of intake based on 
the MSDI approach. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND) Not determined. 
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Table 5:  Summary of Safety Evaluation by the EFSA (FGE.12Rev3) (EFSA CEF Panel, 2012a) 
FL-no EU Register name Structural formula MSDI 1) 
( g/capita/
day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
02.134 
 
2-Cyclohexylethan-1-ol 
 
0.011 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
02.186 
 
Myrtanol 
 
0.37 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
05.157 
 
Isocyclocitral 
 
0.011 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
05.182 
 
2,6,6-
Trimethylcyclohex-2-
ene-1-carboxaldehyde 
 
0.061 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
05.183 
 
4-(2,6,6-
Trimethylcyclohexenyl)
-2-methylbutanal 
 
0.012 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
05.198 
 
alpha-Methyl ional 
 
0.011 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
08.135 
 
4-(2,2,3-
Trimethylcyclopentyl)b
utanoic acid  
43 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
09.342 
 
Cyclogeranyl acetate 
 
0.24 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
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Table 5:  Summary of Safety Evaluation by the EFSA (FGE.12Rev3) (EFSA CEF Panel, 2012a) 
FL-no EU Register name Structural formula MSDI 1) 
( g/capita/
day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
09.670 
 
Myrtanyl acetate 
 
0.58 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
09.829 
 
Ethyl cyclohexyl 
acetate 
 
0.61 
 
Class I 
A3: Intake below 
threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
bw  Body Weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practice 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNBN  Micronucleated Binucleate cells 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
No  Number 
NOAEL No observed adverse effect level 
OECD  Organisation for Economic Co-operation and Development 
RI  Replication Index 
SCF  Scientific Committee on Food 
WHO  World Health Organization 
